J. Rafael Sierra - Concepedia

Concepedia

Author

J. Rafael Sierra

Candiolo Cancer Institute ORCID

Also Known As

J RAFAEL Sierra, J Rafael Sierra, J Sierra, J. R. Sierra, J. Rafael Sierra, J.R. Sierra, Jose Rafael Sierra

49

Publications

1.4K

Citations

11

H-Index

21

Concepts

All Affiliations

Candiolo Cancer Institute Princess Margaret Cancer Centre Alexion Pharmaceuticals (United States)University Health Network AstraZeneca (United States)

JR

About

J. Rafael Sierra is an author at Candiolo Cancer Institute specializing in medicine, cell signaling, and molecular biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	542
2	Cell Biology	2	2	524
3	Molecular Biology	2	2	188
4	Natural Sciences	1	1	170
5	Immunology	1	1	354

J. Rafael Sierra

×

11

Publications

1.4K

Citations

11

H-Index

	Year	Citations
c-MET as a potential therapeutic target and biomarker in cancer J. Rafael Sierra, Ming‐Sound Tsao Therapeutic Advances in Medical Oncology Potential Therapeutic TargetMedicinePharmacologyImmunologyPathology	2011	354
Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages J. Rafael Sierra, Simona Corso, Luisa Caione, The Journal of Experimental Medicine	2008	279
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy J. Rafael Sierra, Virna Cepero, Silvia Giordano Molecular Cancer	2010	225
The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells Julia Petschnigg, Bella Groisman, Max Kotlyar, Nature Methods	2014	180
<i>MET</i> and <i>KRAS</i> Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors Virna Cepero, J. Rafael Sierra, Simona Corso, Cancer Research Chemoprevention StrategyMolecular BiologyCancer BiologyTumor BiologySignaling Pathway	2010	170
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition Simona Corso, Elena Ghiso, Virna Cepero, Molecular Cancer	2010	106
Immunophenotypic characteristics of blast crisis of chronic myeloid leukaemia: correlations with clinico-biological features and survival. Álvaro Urbano-Ispizúa, Francisco Cervantes, Estella Matutes, PubMed	1993	25
Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up Mustafa Nuri Yenerel, Flore Sicre de Fontbrune, Caroline Piatek, Advances in Therapy	2022	22
312 MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors Elena Ghiso, Virna Cepero, J. Rafael Sierra, European Journal of Cancer Supplements Drug TargetSignal TransductionMedicineReceptor Tyrosine KinaseMechanism Of Action	2010	18
Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab Ioannis Tomazos, J. Rafael Sierra, Karissa Johnston, Hematology	2020	18

Page 1